Temat: "SALMETEROL" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid.
Autorzy:: Suryana S; Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang 45363, Indonesia.; Pharmacy Department, Faculty of Mathematics and Natural Sciences, Universitas Garut, Jl. Jati No. 42B, Garut 44151, Indonesia.
Mutakin M; Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang 45363, Indonesia.
Rosandi Y; Geophysic Department, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang 45363, Indonesia.
Hasanah AN; Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang 45363, Indonesia.; Drug Development Study Center, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang 45363, Indonesia.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2022 Jun 05; Vol. 27 (11). Date of Electronic Publication: 2022 Jun 05.
Typ publikacji:: Journal Article
MeSH Terms:: Molecular Imprinting*/methods
Salmeterol Xinafoate/*analysis
Molecular Dynamics Simulation ; Molecularly Imprinted Polymers ; Salmeterol Xinafoate/chemistry ; Solid Phase Extraction/methods

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Autorzy:: Skloot GS; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy. .; Chiesi USA, Inc., Cary, NC, USA. .
Guasconi A; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Lavon BR; FLUIDDA, Kontich, Belgium.
Georges G; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
De Backer W; Department of Respiratory Medicine, University of Antwerp, Antwerp, Belgium.
Galkin D; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Cortellini M; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Panni I; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Bates JHT; Departments of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2023 Oct 06; Vol. 24 (1), pp. 244. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:: Journal Article
MeSH Terms:: Glycopyrrolate*
Pulmonary Disease, Chronic Obstructive*/diagnostic imaging
Pulmonary Disease, Chronic Obstructive*/drug therapy
Humans ; Formoterol Fumarate ; Beclomethasone ; Muscarinic Antagonists ; Administration, Inhalation ; Fluticasone-Salmeterol Drug Combination ; Drug Combinations ; Adrenergic beta-2 Receptor Agonists ; Bronchodilator Agents

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
Autorzy:: Tashkin DP; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Ohar JA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Medicine at Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Koltun A; Viatris/Mylan Inc., Canonsburg, PA, USA.
Allan R; Viatris/Mylan Pharma UK Ltd., UK.
Ward JK; Viatris/Mylan Pharma UK Ltd., UK.; Pokaż więcej
Źródło:: Pulmonary medicine [Pulm Med] 2021 Mar 17; Vol. 2021, pp. 8881895. Date of Electronic Publication: 2021 Mar 17 (Print Publication: 2021).
Typ publikacji:: Journal Article; Review
MeSH Terms:: Asthma*/drug therapy
Asthma*/epidemiology
Asthma*/physiopathology
Bronchodilator Agents*/pharmacokinetics
Bronchodilator Agents*/therapeutic use
Fluticasone-Salmeterol Drug Combination*/pharmacokinetics
Fluticasone-Salmeterol Drug Combination*/therapeutic use
Glucocorticoids*/pharmacokinetics
Glucocorticoids*/therapeutic use
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/epidemiology
Pulmonary Disease, Chronic Obstructive*/physiopathology
Administration, Inhalation ; Drugs, Generic/pharmacokinetics ; Drugs, Generic/therapeutic use ; Health Services Needs and Demand/statistics & numerical data ; Humans ; Nebulizers and Vaporizers ; Powders/pharmacokinetics ; Powders/therapeutic use ; Practice Guidelines as Topic ; Standard of Care ; Therapeutic Equivalency

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: A cautionary tale of multiple-dose drug products: Fluticasone and salmeterol combination inhaler waste.
Autorzy:: Aeng ESY; Pharmacy Department, Fraser Health Authority, Surrey, British Columbia, Canada.
Dhaliwal MM; Pharmacy Department, Fraser Health Authority, Surrey, British Columbia, Canada.
Tejani AM; Pharmacy Department, Fraser Health Authority, Surrey, British Columbia, Canada.; Pokaż więcej
Źródło:: Journal of evaluation in clinical practice [J Eval Clin Pract] 2020 Dec; Vol. 26 (6), pp. 1699-1702. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Asthma*/drug therapy
Bronchodilator Agents*/therapeutic use
Fluticasone*/therapeutic use
Salmeterol Xinafoate*/therapeutic use
Administration, Inhalation ; Canada ; Drug Combinations ; Humans ; Nebulizers and Vaporizers ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Autorzy:: Huang TM; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Kuo KC; Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Wang YH; Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Wang CY; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Lai CC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan. .
Wang HC; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. .
Chen L; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.; Pokaż więcej
Corporate Authors:: On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)
Źródło:: BMC infectious diseases [BMC Infect Dis] 2020 Sep 25; Vol. 20 (1), pp. 706. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Mycobacterium tuberculosis*
Adrenal Cortex Hormones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Tuberculosis/*epidemiology
Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Budesonide, Formoterol Fumarate Drug Combination/administration & dosage ; Budesonide, Formoterol Fumarate Drug Combination/adverse effects ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Fluticasone-Salmeterol Drug Combination/adverse effects ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Propensity Score ; Risk Factors ; Taiwan/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization.
Autorzy:: Ainali NM; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Xanthopoulou E; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Michailidou G; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Zamboulis A; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Bikiaris DN; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2020 Aug 26; Vol. 25 (17). Date of Electronic Publication: 2020 Aug 26.
Typ publikacji:: Journal Article
MeSH Terms:: Fluticasone*/chemistry
Fluticasone*/pharmacokinetics
Fluticasone*/pharmacology
Salmeterol Xinafoate*/chemistry
Salmeterol Xinafoate*/pharmacokinetics
Salmeterol Xinafoate*/pharmacology
Administration, Inhalation ; Capsules ; Delayed-Action Preparations/chemistry ; Delayed-Action Preparations/pharmacokinetics ; Delayed-Action Preparations/pharmacology ; Humans ; Particle Size ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Study on the Effect of Self-Made Lifei Dingchuan Decoction Combined with Western Medicine on Cough Variant Asthma.
Autorzy:: Li J; Department of Respiratory Medicine, Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528000, China.
Huang Z; The Third School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510145, China.; Department of Traditional Chinese Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, Guangdong 511518, China.
Li K; The Eighth School of Clinical Medicine, Guangzhou University of Chinese Medicine, Foshan, Guangdong 528000, China.
Jian X; Department of Respiratory Medicine, Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528000, China.
Liang B; Department of Respiratory Medicine, Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528000, China.; The Eighth School of Clinical Medicine, Guangzhou University of Chinese Medicine, Foshan, Guangdong 528000, China.; Pokaż więcej
Źródło:: Computational and mathematical methods in medicine [Comput Math Methods Med] 2022 Sep 12; Vol. 2022, pp. 9803552. Date of Electronic Publication: 2022 Sep 12 (Print Publication: 2022).
Typ publikacji:: Journal Article; Retracted Publication
MeSH Terms:: Asthma*/drug therapy
Cough*/drug therapy
Acetates ; Carbon Dioxide ; Cyclopropanes ; Fluticasone/therapeutic use ; Humans ; Oxygen ; Powders/therapeutic use ; Quinolines ; Salmeterol Xinafoate/therapeutic use ; Sulfides ; Tablets/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease.
Autorzy:: Yang Y; Department of Pharmacology and Medicinal Chemistry, Jiangsu Vocational College of Medicine, Yancheng, 224005, Jiangsu, People's Republic of China.
Huang L; Department of Pharmacology and Medicinal Chemistry, Jiangsu Vocational College of Medicine, Yancheng, 224005, Jiangsu, People's Republic of China.
Tian C; Department of Pharmacology and Medicinal Chemistry, Jiangsu Vocational College of Medicine, Yancheng, 224005, Jiangsu, People's Republic of China.
Qian B; Department of Pharmacology and Medicinal Chemistry, Jiangsu Vocational College of Medicine, Yancheng, 224005, Jiangsu, People's Republic of China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2022 Jul 19; Vol. 12 (1), pp. 12334. Date of Electronic Publication: 2022 Jul 19.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Bronchodilator Agents*/adverse effects
Pulmonary Disease, Chronic Obstructive*
Administration, Inhalation ; Albuterol/therapeutic use ; Androstadienes/pharmacology ; Animals ; Anti-Inflammatory Agents/therapeutic use ; Drug Combinations ; Fluticasone/pharmacology ; Fluticasone/therapeutic use ; Rats ; Salmeterol Xinafoate/pharmacology ; Salmeterol Xinafoate/therapeutic use ; Saponins ; Triterpenes

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age.
Autorzy:: Yoshihara S; Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.
Tsubaki T; Tsubaki Children's Clinic, Chiba, Japan.
Ikeda M; Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Lenney W; Global Medical Expert, GSK, Brentford, London, UK.; Respiratory Child Health, Keele University, Staffordshire, UK.
Tomiak R; Global respiratory franchise, GSK, Brentford, London, UK.
Hattori T; Global respiratory franchise, GSK, Brentford, London, UK.
Hashimoto K; Respiratory Medicines Development, GlaxoSmithKline K.K., Tokyo, Japan.
Soutome T; Biomedical Data Sciences Department, GlaxoSmithKline K.K., Tokyo, Japan.
Kato S; Clinical Operations Department, GlaxoSmithKline K.K., Tokyo, Japan.; Pokaż więcej
Źródło:: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology [Pediatr Allergy Immunol] 2019 Mar; Vol. 30 (2), pp. 195-203. Date of Electronic Publication: 2019 Feb 06.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Asthma/*drug therapy
Bronchodilator Agents/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Administration, Inhalation ; Bronchodilator Agents/adverse effects ; Child, Preschool ; Double-Blind Method ; Fluticasone-Salmeterol Drug Combination/adverse effects ; Follow-Up Studies ; Humans ; Infant ; Japan ; Severity of Illness Index ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Uncovering the regional localization of inhaled salmeterol retention in the lung.
Autorzy:: Bäckström E; a Drug Metabolism and Pharmacokinetics, Respiratory, Inflammation and Autoimmunity IMED Biotech Unit , AstraZeneca , Gothenburg , Sweden.
Hamm G; b Pathology Sciences, Drug Safety & Metabolism IMED Biotech Unit , AstraZeneca , Cambridge , UK.
Nilsson A; c Biomolecular Mass Spectrometry Imaging, National Resource for MSI, Science for Life Laboratory, Dept. of Pharmaceutical Biosciences , Uppsala University , Uppsala , Sweden.
Fihn BM; a Drug Metabolism and Pharmacokinetics, Respiratory, Inflammation and Autoimmunity IMED Biotech Unit , AstraZeneca , Gothenburg , Sweden.
Strittmatter N; b Pathology Sciences, Drug Safety & Metabolism IMED Biotech Unit , AstraZeneca , Cambridge , UK.
Andrén P; c Biomolecular Mass Spectrometry Imaging, National Resource for MSI, Science for Life Laboratory, Dept. of Pharmaceutical Biosciences , Uppsala University , Uppsala , Sweden.
Goodwin RJA; b Pathology Sciences, Drug Safety & Metabolism IMED Biotech Unit , AstraZeneca , Cambridge , UK.
Fridén M; a Drug Metabolism and Pharmacokinetics, Respiratory, Inflammation and Autoimmunity IMED Biotech Unit , AstraZeneca , Gothenburg , Sweden.; d Translational PKPD Group, Department of Pharmaceutical Biosciences , Uppsala University , Uppsala , Sweden.; Pokaż więcej
Źródło:: Drug delivery [Drug Deliv] 2018 Nov; Vol. 25 (1), pp. 838-845.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Bronchi/*metabolism
Bronchodilator Agents/*administration & dosage
Lung/*metabolism
Pulmonary Alveoli/*metabolism
Respiratory Mucosa/*metabolism
Salmeterol Xinafoate/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/metabolism ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Adrenergic beta-2 Receptor Agonists/pharmacology ; Animals ; Bronchi/cytology ; Bronchi/diagnostic imaging ; Bronchi/drug effects ; Bronchodilator Agents/metabolism ; Bronchodilator Agents/pharmacokinetics ; Bronchodilator Agents/pharmacology ; Cluster Analysis ; Deuterium ; Injections, Intravenous ; Lung/cytology ; Lung/diagnostic imaging ; Lung/drug effects ; Male ; Mass Spectrometry ; Molecular Imaging ; Pharmaceutical Vehicles/chemistry ; Phosphatidylethanolamines/chemistry ; Polyethylene Glycols/chemistry ; Polysorbates/chemistry ; Pulmonary Alveoli/cytology ; Pulmonary Alveoli/diagnostic imaging ; Pulmonary Alveoli/drug effects ; Rats, Wistar ; Respiratory Mucosa/cytology ; Respiratory Mucosa/diagnostic imaging ; Respiratory Mucosa/drug effects ; Respiratory Tract Absorption ; Salmeterol Xinafoate/metabolism ; Salmeterol Xinafoate/pharmacokinetics ; Salmeterol Xinafoate/pharmacology ; Tissue Distribution

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices.
Autorzy:: Mannan H; Translational Health Research Institute, Western Sydney University, Campbelltown, NSW, Australia. .
Foo SW; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.; Department of Respiratory and Sleep Medicine, Campbelltown and Camden Hospitals, Campbelltown, NSW, Australia.
Cochrane B; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.; Department of Respiratory and Sleep Medicine, Campbelltown and Camden Hospitals, Campbelltown, NSW, Australia.; Pokaż więcej
Źródło:: BMC research notes [BMC Res Notes] 2019 Feb 20; Vol. 12 (1), pp. 94. Date of Electronic Publication: 2019 Feb 20.
Typ publikacji:: Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:: Metered Dose Inhalers*
Outcome Assessment, Health Care*
Bronchodilator Agents/*pharmacology
Fluticasone/*pharmacology
Pulmonary Disease, Chronic Obstructive/*drug therapy
Salmeterol Xinafoate/*pharmacology
Aged ; Bronchodilator Agents/administration & dosage ; Cross-Over Studies ; Female ; Fluticasone/administration & dosage ; Humans ; Male ; Middle Aged ; Salmeterol Xinafoate/administration & dosage ; Single-Blind Method

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation.
Autorzy:: Sadiq MW; Clinical and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Safety Sciences, AstraZeneca, Gothenburg, Sweden.; R&D, AstraZeneca, Gothenburg, Sweden.
Holz O; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.; Biomedical Research in End-stage and Obstructive Lung Disease (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
Ellinghusen BD; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Faulenbach C; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Müller M; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Badorrek P; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Eriksson UG; Clinical and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Safety Sciences, AstraZeneca, Gothenburg, Sweden.; R&D, AstraZeneca, Gothenburg, Sweden.
Fridén M; Drug Metabolism and Pharmacokinetics, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, AstraZeneca, Gothenburg, Sweden.; Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden.
Stomilovic S; Drug Metabolism and Pharmacokinetics, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, AstraZeneca, Gothenburg, Sweden.; Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Lundqvist AJ; Drug Metabolism and Pharmacokinetics, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, AstraZeneca, Gothenburg, Sweden.; Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Hohlfeld JM; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.; Biomedical Research in End-stage and Obstructive Lung Disease (BREATH), German Center for Lung Research (DZL), Hannover, Germany.; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2021 Nov; Vol. 178 (22), pp. 4440-4451. Date of Electronic Publication: 2021 Aug 11.
Typ publikacji:: Journal Article
MeSH Terms:: Pharmaceutical Preparations*
Albuterol ; Fluticasone ; Humans ; Lung ; Salmeterol Xinafoate

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
Autorzy:: Bjermer L; Department of Respiratory medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden.
van Boven JFM; Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.
Costa-Scharplatz M; Novartis Sverige AB, Täby, Sweden.
Keininger DL; Novartis Pharma AG, Basel, Switzerland.
Gutzwiller FS; Novartis Pharma AG, Basel, Switzerland.
Lisspers K; Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
Mahon R; Novartis Ireland Limited, Dublin, Ireland.
Olsson P; Novartis Sverige AB, Täby, Sweden.
Roche N; Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and University Paris Descartes, Paris, France. .; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2017 Dec 11; Vol. 18 (1), pp. 206. Date of Electronic Publication: 2017 Dec 11.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Models, Economic*
Cost-Benefit Analysis/*methods
Fluticasone-Salmeterol Drug Combination/*economics
Glycopyrrolate/*economics
Indans/*economics
Population Surveillance/*methods
Pulmonary Disease, Chronic Obstructive/*economics
Quinolones/*economics
Aged ; Double-Blind Method ; Drug Combinations ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Glycopyrrolate/administration & dosage ; Humans ; Indans/administration & dosage ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Quinolones/administration & dosage ; Sweden/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Reduced suppressive effect of β 2 -adrenoceptor agonist on fibrocyte function in severe asthma.
Autorzy:: Lo CY; Airway Disease Section, National Heart and Lung Institute, Imperial College London and Biomedical Research Unit, Royal Brompton Hospital, London, UK.; Department of Thoracic Medicine, Chang Gung Medical Foundation, Chang Gung University College of Medicine, Taipei, Taiwan.
Michaeloudes C; Airway Disease Section, National Heart and Lung Institute, Imperial College London and Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Bhavsar PK; Airway Disease Section, National Heart and Lung Institute, Imperial College London and Biomedical Research Unit, Royal Brompton Hospital, London, UK. .; Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, SW3 6LY, UK. .
Huang CD; Department of Thoracic Medicine, Chang Gung Medical Foundation, Chang Gung University College of Medicine, Taipei, Taiwan.
Chang PJ; Airway Disease Section, National Heart and Lung Institute, Imperial College London and Biomedical Research Unit, Royal Brompton Hospital, London, UK.; Department of Thoracic Medicine, Chang Gung Medical Foundation, Chang Gung University College of Medicine, Taipei, Taiwan.
Wang CH; Department of Thoracic Medicine, Chang Gung Medical Foundation, Chang Gung University College of Medicine, Taipei, Taiwan.
Kuo HP; Department of Thoracic Medicine, Chang Gung Medical Foundation, Chang Gung University College of Medicine, Taipei, Taiwan.
Chung KF; Airway Disease Section, National Heart and Lung Institute, Imperial College London and Biomedical Research Unit, Royal Brompton Hospital, London, UK.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2017 Nov 21; Vol. 18 (1), pp. 194. Date of Electronic Publication: 2017 Nov 21.
Typ publikacji:: Journal Article
MeSH Terms:: Severity of Illness Index*
Adrenergic beta-2 Receptor Agonists/*pharmacology
Asthma/*physiopathology
Fibroblasts/*drug effects
Leukocytes, Mononuclear/*drug effects
Salmeterol Xinafoate/*pharmacology
Adrenergic beta-2 Receptor Agonists/therapeutic use ; Adult ; Asthma/drug therapy ; Asthma/immunology ; Cells, Cultured ; Dose-Response Relationship, Drug ; Female ; Fibroblasts/physiology ; Humans ; Leukocytes, Mononuclear/physiology ; Male ; Middle Aged ; Salmeterol Xinafoate/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: The stimulation and inhibition of beta-2 adrenergic receptor on the inflammatory responses of ovary and immune system in the aged laying hens.
Autorzy:: Hatefi A; Department of Animal Science, University of Tehran, Karaj, Iran. .
Zare Shahneh A; Department of Animal Science, University of Tehran, Karaj, Iran.
Ansari Pirsaraie Z; Department of Animal Science, Sari Agricultural and Natural Resources University, Sari, Iran.
Alizadeh AM; Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Atashnak MP; Molecular Biology and Biochemistry Department, Simon Fraser University, Burnaby, British Columbia, Canada.
Masoudi R; Animal Science Research Institute of Iran (ASRI), Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran.
Pio F; Molecular Biology and Biochemistry Department, Simon Fraser University, Burnaby, British Columbia, Canada.; Pokaż więcej
Źródło:: BMC veterinary research [BMC Vet Res] 2021 May 22; Vol. 17 (1), pp. 195. Date of Electronic Publication: 2021 May 22.
Typ publikacji:: Journal Article
MeSH Terms:: Chickens/*metabolism
Immune System/*physiology
Ovary/*metabolism
Receptors, Adrenergic, beta-2/*metabolism
Adrenergic beta-2 Receptor Agonists/pharmacology ; Adrenergic beta-Antagonists/pharmacology ; Androgens/blood ; Animals ; Chickens/immunology ; Cytokines/genetics ; Cytokines/metabolism ; Enzyme-Linked Immunosorbent Assay/veterinary ; Estradiol/blood ; Female ; Immune System/drug effects ; Immunity, Cellular ; Immunity, Humoral ; Inflammation Mediators/metabolism ; Ovary/drug effects ; Ovary/immunology ; Progesterone/blood ; Propranolol/pharmacology ; Salmeterol Xinafoate/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Autorzy:: Chen F; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; School of Medicine, Tsinghua University, Beijing, China.
Shi Q; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; School of Medicine, Tsinghua University, Beijing, China.
Pei F; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA.
Vogt A; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA.
Porritt RA; Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Biomedical Sciences, Infectious and Immunologic Diseases Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Garcia G Jr; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA.
Gomez AC; Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cheng MH; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Schurdak ME; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA.
Liu B; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Chan SY; Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Division of Cardiology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Arumugaswami V; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA.
Stern AM; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA.
Taylor DL; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA.
Arditi M; Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Biomedical Sciences, Infectious and Immunologic Diseases Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Bahar I; Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA, USA.; Pokaż więcej
Źródło:: Molecular systems biology [Mol Syst Biol] 2021 Aug; Vol. 17 (8), pp. e10239.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: COVID-19 Drug Treatment*
Antiviral Agents/*pharmacology
Drug Evaluation, Preclinical/*methods
Virus Internalization/*drug effects
Angiotensin-Converting Enzyme 2/genetics ; Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; COVID-19/genetics ; COVID-19/virology ; Chlorocebus aethiops ; Drug Repositioning ; HEK293 Cells ; Host-Pathogen Interactions/drug effects ; Host-Pathogen Interactions/physiology ; Humans ; Imidazoles/pharmacology ; Pyrazines/pharmacology ; SARS-CoV-2/drug effects ; SARS-CoV-2/pathogenicity ; Salmeterol Xinafoate/pharmacology ; Vero Cells

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Autorzy:: Zhong N; a State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University , Guangzhou , Guangdong , China.
Wang C; b Institute of Respiratory Disease, Xin Qiao Hospital, Third Military Medical University , Chongqing City , Chongqing , China.
Zhou X; c Department of Respiratory Medicine , Southwest Hospital, Third Military Medical University , Chongqing City , Chongqing , China.
Zhang N; a State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University , Guangzhou , Guangdong , China.
Humphries M; d Beijing Novartis Pharma Co. Ltd. , Shanghai , China.
Wang L; d Beijing Novartis Pharma Co. Ltd. , Shanghai , China.
Patalano F; e Novartis Pharma AG , Basel , Switzerland.
Banerji D; f Novartis Pharmaceuticals Corporation , East Hanover , New Jersey , USA.; Pokaż więcej
Źródło:: COPD [COPD] 2016 Dec; Vol. 13 (6), pp. 686-692. Date of Electronic Publication: 2016 Aug 11.
Typ publikacji:: Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*therapeutic use
Bronchodilator Agents/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Glycopyrrolate/*therapeutic use
Indans/*therapeutic use
Muscarinic Antagonists/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Quinolones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/administration & dosage ; Aged ; Bronchodilator Agents/administration & dosage ; China ; Disease Progression ; Double-Blind Method ; Drug Combinations ; Dyspnea/etiology ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Forced Expiratory Volume ; Glycopyrrolate/administration & dosage ; Humans ; Indans/administration & dosage ; Male ; Middle Aged ; Muscarinic Antagonists/administration & dosage ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinolones/administration & dosage ; Vital Capacity

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Understanding the Clinical Implications of Individual Patient Characteristics and Treatment Choice on the Risk of Exacerbation in Asthma Patients with Moderate–Severe Symptoms
Autorzy:: Singh, Dave
Oosterholt, Sean
Pavord, Ian
Garcia, Gabriel
Abhijith PG
Della Pasqua, OscarAff2, Aff6, IDs12325023025902_cor6; Pokaż więcej
Źródło:: Advances in Therapy. 40(10):4606-4625

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 19.

Tytuł:: Comparison of fractional exhaled nitric oxide in asthmatics with and without allergic rhinitis.
Autorzy:: Galiniak S; Medical College of Rzeszów University, Rzeszów, Poland.
Rachel M; Medical College of Rzeszów University, Rzeszów, Poland.; Allergology Department, Provincial Hospital No 2, Rzeszów, Poland.; Pokaż więcej
Źródło:: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2021 Mar; Vol. 26 (2), pp. 174-183. Date of Electronic Publication: 2021 Jan 12.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Asthma/*diagnosis
Nitric Oxide/*analysis
Rhinitis, Allergic/*diagnosis
Adolescent ; Adrenal Cortex Hormones/therapeutic use ; Adult ; Aged ; Asthma/complications ; Asthma/drug therapy ; Asthma/metabolism ; Biomarkers/analysis ; Breath Tests ; Bronchodilator Agents/therapeutic use ; Budesonide/therapeutic use ; Case-Control Studies ; Exhalation/physiology ; Female ; Fluticasone/therapeutic use ; Humans ; Male ; Middle Aged ; Nitric Oxide/metabolism ; Rhinitis, Allergic/complications ; Rhinitis, Allergic/drug therapy ; Rhinitis, Allergic/metabolism ; Salmeterol Xinafoate/therapeutic use ; Spirometry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Autorzy:: Mehta R; GlaxoSmithKline, Research Triangle Park, NC, USA, .
Riddell K
Gupta A
Louey MD
Chan RH; Pokaż więcej
Źródło:: Clinical drug investigation [Clin Drug Investig] 2015 May; Vol. 35 (5), pp. 319-26.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Dry Powder Inhalers*
Metered Dose Inhalers*
Bronchodilator Agents/*pharmacokinetics
Fluticasone-Salmeterol Drug Combination/*pharmacokinetics
Adult ; Bronchodilator Agents/adverse effects ; Bronchodilator Agents/blood ; Cross-Over Studies ; Drug Combinations ; Female ; Fluticasone-Salmeterol Drug Combination/adverse effects ; Fluticasone-Salmeterol Drug Combination/blood ; Humans ; Male ; Middle Aged ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""SALMETEROL"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji